ESR1 and invasive breast carcinoma: In that same 2017 annual report, “more than 126,740 ODX test reports were delivered for use for treatment planning.”37 The substantial majority (approximately 85%) of historical revenues from ODX testing comes from invasive breast carcinoma testing,31, 37, 38 suggesting that approximately 107,729 ER+ invasive breast cases were received for ODX testing in 2017.